Kirin Holdings Company, Limited Sponsored ADR (KNBWY) – PRNewswire
-
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
-
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
-
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
-
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
-
Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
-
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
-
New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life
-
Kyowa Kirin Presents Real-World Findings at ASBMR Annual Meeting Highlighting Progressive Disease Burden of X-linked Hypophosphatemia (XLH)
-
Kyowa Kirin to Present New Research on X-linked Hypophosphatemia (XLH) at ASBMR Annual Meeting
-
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
-
Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023
-
Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
-
Kyowa Kirin Designs New North American Headquarters to Accelerate Innovation, Collaboration, Culture
-
Kyowa Kirin Appoints Gunnar F. Kaufmann, Ph.D., as Chief Research Officer, North America
-
Kyowa Kirin Launches Effort to Educate Healthcare Providers on Blood Involvement in Mycosis Fungoides and Sézary Syndrome
-
Kyowa Kirin Presents New Findings from Real-World Study in Parkinson's Disease at the 2023 IAPRD Conference
-
Kyowa Kirin North America Assumes Commercial Leadership Role for CRYSVITA® (burosumab-twza) Injection in North America
-
Kyowa Kirin Appoints Pharma Industry Leader Steve Schaefer as President, North America to Manage Next Phase of Growth
-
Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023
-
Kyowa Kirin Announces Acceptance for Presentation of Two Posters at the American Academy of Dermatology Annual Meeting 2023
-
New Effort Sheds Light on Burdens and Benefits of Parkinson's Care Partner Experience, Offers Insights for Navigating Journey
-
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
-
Kyowa Kirin Launches New Effort to Educate Patients About the Role of Adenosine in Parkinson's Disease (PD) and Treatment of "Off" Episodes with NOURIANZ® (istradefylline)
-
Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data
-
Kyowa Kirin to Host Expert Roundtable Addressing Racial Health Inequities in Cancer Care
-
Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director
-
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
-
La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc.
-
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA
-
Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
-
Kyowa Kirin North America Appoints Paula Soteropoulos to Board of Directors
-
Kyowa Kirin Launches New Efforts to Educate and Engage Physicians and Patients with Rare Forms of Cutaneous T-Cell Lymphoma About Treatment with POTELIGEO® (mogamulizumab-kpkc)
-
Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
-
Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
-
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
-
New Publication Offers Insight into POTELIGEO® (mogamulizumab-kpkc) Treatment Response in Cutaneous T-cell Lymphoma Patients with Varying Levels of Blood Involvement
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
-
MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib
-
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
-
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
-
Kyowa Kirin North America Announces Key Executive Appointments in R&D and Medical Affairs As Late-Stage Assets Move Toward Key Milestones
-
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
-
MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval
-
Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory
-
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis
-
A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan
-
New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma
-
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
-
Kyowa Kirin North America Announces Recipients of Patient Education Grants to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)
Back to KNBWY Stock Lookup
